MSD stops prostate cancer trial

A trial involving drug candidate Keytruda has been stopped, as preliminary data has failed to show that the drug has an effect.

Photo: MSD / PR

US-based pharmaceutical company MSD has stopped a trial of its prostate cancer treatment candidate. The trial in question is a combination trial of MSD’s Keytruda and Astrazeneca’s Lynparza.

The trial has been stopped as preliminary data did not show that the drug had any effect on survival rates.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs